ARCT
Price
$14.42
Change
+$0.47 (+3.37%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
378.33M
46 days until earnings call
PDSB
Price
$1.45
Change
-$0.06 (-3.97%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
69.02M
48 days until earnings call
Interact to see
Advertisement

ARCT vs PDSB

Header iconARCT vs PDSB Comparison
Open Charts ARCT vs PDSBBanner chart's image
Arcturus Therapeutics Holdings
Price$14.42
Change+$0.47 (+3.37%)
Volume$7.21K
Capitalization378.33M
PDS Biotechnology
Price$1.45
Change-$0.06 (-3.97%)
Volume$17.19K
Capitalization69.02M
ARCT vs PDSB Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. PDSB commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and PDSB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ARCT: $13.95 vs. PDSB: $1.51)
Brand notoriety: ARCT and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 114% vs. PDSB: 74%
Market capitalization -- ARCT: $378.33M vs. PDSB: $69.02M
ARCT [@Biotechnology] is valued at $378.33M. PDSB’s [@Biotechnology] market capitalization is $69.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARCT and PDSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while PDSB’s TA Score has 3 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 3 bearish.
  • PDSB’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than PDSB.

Price Growth

ARCT (@Biotechnology) experienced а +12.96% price change this week, while PDSB (@Biotechnology) price change was -6.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.00%. For the same industry, the average monthly price growth was +32.55%, and the average quarterly price growth was +15.13%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

PDSB is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($378M) has a higher market cap than PDSB($69M). PDSB YTD gains are higher at: -7.362 vs. ARCT (-17.796). PDSB has higher annual earnings (EBITDA): -33.08M vs. ARCT (-63.92M). ARCT has more cash in the bank: 217M vs. PDSB (40M). PDSB has less debt than ARCT: PDSB (19M) vs ARCT (42.7M). ARCT has higher revenues than PDSB: ARCT (131M) vs PDSB (0).
ARCTPDSBARCT / PDSB
Capitalization378M69M548%
EBITDA-63.92M-33.08M193%
Gain YTD-17.796-7.362242%
P/E RatioN/AN/A-
Revenue131M0-
Total Cash217M40M543%
Total Debt42.7M19M225%
FUNDAMENTALS RATINGS
ARCT vs PDSB: Fundamental Ratings
ARCT
PDSB
OUTLOOK RATING
1..100
1583
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
38
Fair valued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
5956
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (38) in the Pharmaceuticals Major industry is in the same range as ARCT (48). This means that PDSB’s stock grew similarly to ARCT’s over the last 12 months.

PDSB's Profit vs Risk Rating (97) in the Pharmaceuticals Major industry is in the same range as ARCT (100). This means that PDSB’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as PDSB (98). This means that ARCT’s stock grew similarly to PDSB’s over the last 12 months.

PDSB's Price Growth Rating (56) in the Pharmaceuticals Major industry is in the same range as ARCT (59). This means that PDSB’s stock grew similarly to ARCT’s over the last 12 months.

PDSB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ARCT (100). This means that PDSB’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTPDSB
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 15 days ago
86%
Declines
ODDS (%)
Bearish Trend 22 days ago
87%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NRARX49.90N/A
N/A
Neuberger Berman Sustainable Equity R3
GGRAX10.94N/A
N/A
Goldman Sachs Strategic Growth A
JNGTX68.72N/A
N/A
Janus Henderson Glb Tech and Innovt D
HFEIX55.50N/A
N/A
Janus Henderson European Focus I
EMQAX8.78N/A
N/A
Ashmore Emerging Markets Active Eq A

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+4.03%
TRDA - ARCT
52%
Loosely correlated
-0.28%
ABCL - ARCT
51%
Loosely correlated
+3.26%
RGNX - ARCT
50%
Loosely correlated
-0.23%
MRNA - ARCT
50%
Loosely correlated
+0.22%
RXRX - ARCT
50%
Loosely correlated
-1.15%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with RXRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-5.63%
RXRX - PDSB
48%
Loosely correlated
-1.15%
ARCT - PDSB
47%
Loosely correlated
+4.03%
DYN - PDSB
43%
Loosely correlated
-1.98%
AXON - PDSB
43%
Loosely correlated
-1.16%
IDYA - PDSB
43%
Loosely correlated
+1.06%
More